The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy

Lu, Yongzheng; Cui, Xiaolin; Zhang, Li; Wang, Xu; Xu, Yanyan; Qin, Zhen; Liu, Gangqiong; Wang, Qiguang; Tian, Kangkai; Lim, Khoon S.; Charles, C.J.; Zhang, Jinying; Tang, Jiyu

doi:10.14336/ad.2021.0929

Cited by 30 publications

(15 citation statements)

References 257 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we demonstrated that Rb1 administration attenuates arterial endothelial damage, lipid metabolism disruption and inhibits systemic inflammation in a rat model of AS. Disorders of lipid metabolism and endothelial damage are the main pathologic changes in the early stages of AS [ [32] , [33] , [34] ]. Dyslipidemia can induce vascular endothelial injury and regulation of macrophage phenotype, thus accelerating the formation of AS plaques [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Integration of 16S rRNA sequencing and metabolomics to investigate the modulatory effect of ginsenoside Rb1 on atherosclerosis

Liang,

Fu,

Shi

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Integration of 16S rRNA sequencing and metabolomics to investigate the modulatory effect of ginsenoside Rb1 on atherosclerosis

Liang,

Fu,

Shi

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…It was found that the ApoB-100 peptide P210 vaccine significantly attenuated aortic atherosclerosis in a humanized mouse model ( 47 ). The decrease of dose-dependent in apolipoproteins, such as Lp(a), and LDL-C, were observed after the administration of mipomersen in clinical trials ( 13 ). If ApoB proves to be a risk factor for CKD, mipomersen may be an alternative strategy for alleviating such metabolic risk-associated impairment in kidney function.…”

Section: Discussionmentioning

confidence: 99%

“…At present, lipid-lowering therapy by reducing the production of ApoB is mainly used in patients with atherosclerosis ( 10 , 11 ). For example, mipomersen is the first Food and Drug Administration approved antisense ApoB synthesis inhibitor for patients who tolerate statin therapy and are at high CVD risk ( 12 , 13 ). In the study of clinical trials, dose-dependent reductions were produced by mipomersen in different types of ApoB-containing lipoproteins, including lipoprotein (a) [Lp(a)] and low-density lipoprotein-cholesterol (LDL-C) ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

The association of apolipoprotein B with chronic kidney disease in the Chinese population

Liu

Lin

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundWhether serum apolipoprotein B (ApoB) is a risk factor for the development of Chronic kidney disease (CKD) has not been fully established in the general population. Therefore, our study evaluated the correlation between serum ApoB level and CKD to look for an alternative approach for CKD prevention and treatment in the general population.MethodsThere were 146,533 participants in this cross-sectional study. 3,325 participants with more than 2 measurements were enrolled in the retrospective longitudinal study with at least a 3-year follow-up. ApoB was measured by the immunoturbidimetric method in 6 centers. Our study defined CKD as an estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2. The Spearman rank correlation analysis and the Random Forest algorithm were applied to rank the importance of variables determining the levels of eGFR. We used the logistic regression model to explain the correlation between serum ApoB and CKD. We used the Cox model to detect the correlation between baseline serum ApoB and the subsequent occurrence of CKD.ResultsBased on a cross-sectional study, 66.5% of the participants were males, with a median age of 49 (interquartile range [IQR] 43-55). Compared to the non-CKD group, the CKD group has higher levels of lipid profile and fasting glucose as well as the proportion of hypertension and hyperuricemia. The Spearman rank correlation analysis and the Random Forest algorithm revealed that ApoB has the highest correlation with eGFR decline among lipid profiles. The logistic regression analysis revealed that ApoB had a positive correlation with the prevalence of CKD after fully controlling confounders (odds ratio [OR], 1.07; 95% confidence interval [CI]: 1.02-1.11). Moreover, baseline ApoB level was correlated with a new-onset CKD in the longitudinal cohort after full adjustment for confounding factors (hazard ratio [HR], 1.61; 95% CI: 1.02-2.54). The correlation between ApoB level and the new-onset CKD was consistently observed in all sensitivity analyses.ConclusionSerum ApoB had the strongest correlation with CKD among all lipid variables. Moreover, high serum ApoB levels might precede the occurrence of CKD, suggesting that monitoring and reducing serum ApoB levels may provide an alternative method to prevent and treat CKD.

show abstract

“…As shown in Figure 3, we can observe that, independently of the increase in body weight, a triggering risk factor in the development of atherosclerosis is dyslipidemia, which can be of environmental, genetic, or combined origin, initially producing an infiltration of macrophages in the subendothelium, which accumulates until reaching the early lesion; in the intermediate lesion, there is already an intra and extracellular accumulation, which gives rise to the development of the extracellular lipid nucleus or atheroma [61]. In the late stages, a fibrotic layer is produced and calcified, leading to complicated lesions, causing plaque rupture, thrombosis, and blockage of blood flow.…”

Section: Dyslipidemia As a Lox-1 Inducermentioning

confidence: 99%

LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review

Sánchez-León,

Loaeza-Reyes,

Matias-Cervantes

et al. 2024

IJMS

View full text Add to dashboard Cite

LOX-1, ORL-1, or lectin-like oxidized low-density lipoprotein receptor 1 is a transmembrane glycoprotein that binds and internalizes ox-LDL in foam cells. LOX-1 is the main receptor for oxidized low-density lipoproteins (ox-LDL). The LDL comes from food intake and circulates through the bloodstream. LOX-1 belongs to scavenger receptors (SR), which are associated with various cardiovascular diseases. The most important and severe of these is the formation of atherosclerotic plaques in the intimal layer of the endothelium. These plaques can evolve into complicated thrombi with the participation of fibroblasts, activated platelets, apoptotic muscle cells, and macrophages transformed into foam cells. This process causes changes in vascular endothelial homeostasis, leading to partial or total obstruction in the lumen of blood vessels. This obstruction can result in oxygen deprivation to the heart. Recently, LOX-1 has been involved in other pathologies, such as obesity and diabetes mellitus. However, the development of atherosclerosis has been the most relevant due to its relationship with cerebrovascular accidents and heart attacks. In this review, we will summarize findings related to the physiologic and pathophysiological processes of LOX-1 to support the detection, diagnosis, and prevention of those diseases.

show abstract

The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy

Cited by 30 publications

References 257 publications

Integration of 16S rRNA sequencing and metabolomics to investigate the modulatory effect of ginsenoside Rb1 on atherosclerosis

Integration of 16S rRNA sequencing and metabolomics to investigate the modulatory effect of ginsenoside Rb1 on atherosclerosis

The association of apolipoprotein B with chronic kidney disease in the Chinese population

LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review

Contact Info

Product

Resources

About